← Leaderboards
Paul Werner Buehler
University Of Colorado Denver
$4,588,385
Attributed
$14,731,438
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,731,438 · 7
By mechanism
R01$13,681,438 · 6
R44$1,050,000 · 1
Top collaborators
- David Charles Irwin16 shared
- Andre Francis Palmer16 shared
- Pedro Cabrales8 shared
- Angelo D'Alessandro4 shared
- David W Wood4 shared
- Esma Alp1 shared
- Narayana Aluru1 shared
- Allan Doctor1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- David Charles Irwin$10,493,842
- Andre Francis Palmer$9,637,181
- Angelo D'alessandro$12,761,823
- York E Miller$6,348,289
Others in their field
Other Emerging Leaders on “Hemoglobin”
- Ionut Bebu · George Washington University$14,825,594
- Barbara Halina Braffett · George Washington University$14,825,594
- Michael P Harms · Washington University$13,645,932
- Colin Masters · University Of Melbourne$10,651,748
- Angelo D'alessandro · University Of Colorado Denver$7,836,369
- Pearl McElfish · Univ Of Arkansas For Med Scis$7,834,110
Research focus
HemoglobinPlasmaTissuesLungIn VitroToxic EffectAnimal ModelBloodErythrocytesIn VivoComplexHemolysisResponseProteinsDimerCellsEngineeringMonocyteMacrophageCirculationDesignBlood VesselsDrug KineticsAffinity
Grant awards (22)
Preclinical Evaluation of a Peptide-amphiphile Derived Toroidal Oxygen Carrier$715,110
R01 · FY2025 · HL
The paradoxical response to iron in pulmonary hypertension of sickle cell disease$666,831
R01 · FY2025 · HL
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$631,536
R01 · FY2025 · HL · contact PI
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases$623,543
R01 · FY2025 · HL
The paradoxical response to iron in pulmonary hypertension of sickle cell disease$657,115
R01 · FY2024 · HL
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$629,898
R01 · FY2024 · HL · contact PI
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$625,741
R01 · FY2024 · HL
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases$611,072
R01 · FY2024 · HL
Engineering a novel biomaterial for oxygen transport applications$585,516
R01 · FY2024 · HL
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute$1,050,000
R44 · FY2023 · HL
The paradoxical response to iron in pulmonary hypertension of sickle cell disease$674,111
R01 · FY2023 · HL
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$653,723
R01 · FY2023 · HL · contact PI
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$646,411
R01 · FY2023 · HL
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases$623,543
R01 · FY2023 · HL
Engineering a novel biomaterial for oxygen transport applications$613,884
R01 · FY2023 · HL
The paradoxical response to iron in pulmonary hypertension of sickle cell disease$711,122
R01 · FY2022 · HL
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$701,968
R01 · FY2022 · HL · contact PI
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$656,753
R01 · FY2022 · HL
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases$648,518
R01 · FY2022 · HL
Engineering a novel biomaterial for oxygen transport applications$636,624
R01 · FY2022 · HL
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$703,990
R01 · FY2021 · HL
Engineering a novel biomaterial for oxygen transport applications$664,429
R01 · FY2021 · HL